AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20102140 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance education intervention for rural nurses regarding mammography screening.
Number of subjects: 0
Study 20102140 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 17494667 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton MR spectroscopy
Number of subjects: 20
Study 17494667 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI volumetry
Number of subjects: 20
Study 17494667 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 15789016 — intervention group
Group type: EXPERIMENTAL
Intervention: Docking reconstructions
Number of subjects: 20
Study 15789016 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton reconstructions
Number of subjects: 20
Study 15789016 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference screw reconstructions
Number of subjects: 20
Study 15789016 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure‐eight reconstructions
Number of subjects: 20
Study 15789016 — intervention group
Group type: COMPARATOR
Intervention: Intact ligaments
Number of subjects: 20
Study 11870792 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser treatment (1-5 sessions)
Number of subjects: 29
Study 11870792 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser treatment (5 sessions)
Number of subjects: 29
Study 11870792 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser treatment
Number of subjects: 29
Study 10094216 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg plus Fluticasone propionate 88 microg
Number of subjects: 136
Study 10094216 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 42 microg plus Fluticasone propionate 220 microg
Number of subjects: 136
Study 10094216 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg
Number of subjects: 136
Study 10094216 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 220 microg
Number of subjects: 136
Study 10094216 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol 42 microg
Number of subjects: 136
Study 7595744 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVmP-VB
Number of subjects: 64
Study 7595744 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-MOPP
Number of subjects: 64
Study 7595744 — intervention group
Group type: COMPARATOR
Intervention: IFN
Number of subjects: 64
Study 7595744 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 64
Study 2134116 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (800 mg t.i.d.)
Number of subjects: 30
Study 2134116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30368018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab (9 mg)
Number of subjects: 98
Study 30368018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 30368018 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab
Number of subjects: 98
Study 28578900 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Home Offerings via the Mealtime Environment Plus program (intervention)
Number of subjects: 160
Study 28578900 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 27960007 — intervention group
Group type: EXPERIMENTAL
Intervention: Literate language intervention (4 instructional units on prepositions, conjunctions, adverbs, and negations, delivered by paraprofessionals in small groups, 20-min lessons 4 times a week for 12 weeks)
Number of subjects: 82
Study 27960007 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 82
Study 24804272 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion protocol (transfusion if hemoglobin dropped below 9.9 g dL(-1))
Number of subjects: 58
Study 24804272 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion protocol (transfusion if hemoglobin dropped below 7.7 g dL(-1))
Number of subjects: 58
Study 21910025 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted efficacy intervention (MEI)
Number of subjects: 140
Study 21910025 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 140
Study 30049303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg
Number of subjects: 21
Study 30049303 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 21
Study 30049303 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of Mirogabalin 15 mg with Metformin 850 mg
Number of subjects: 21
Study 18043099 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral neck exploration
Number of subjects: 91
Study 18043099 — intervention group
Group type: COMPARATOR
Intervention: Bilateral neck exploration
Number of subjects: 91
Study 16198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler tissue imaging-derived parameters of peak systolic velocity
Number of subjects: 0
Study 16198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler tissue imaging-derived parameters of myocardial acceleration during isovolumic contraction
Number of subjects: 0
Study 16198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for peak systolic velocity
Number of subjects: 0
Study 16198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for peak systolic velocity
Number of subjects: 0
Study 16198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for myocardial acceleration during isovolumic contraction
Number of subjects: 0
Study 16198888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraobserver reliability for myocardial acceleration during isovolumic contraction
Number of subjects: 0
Study 11995260 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (5-10 mg once daily for three months)
Number of subjects: 31
Study 10784382 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic supplementation with 15 g of arginine aspartate daily for 14 days
Number of subjects: 14
Study 10784382 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate‐based placebo
Number of subjects: 14
Study 7568859 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphasic injection of 38 g of iodine
Number of subjects: 487
Study 7568859 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniphasic injection of 26 g of iodine
Number of subjects: 487
Study 7568859 — intervention group
Group type: COMPARATOR
Intervention: Biphasic injection
Number of subjects: 487
Study 2122131 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with mitomycin C (MMC), tegafur, and PSK
Number of subjects: 255
Study 2122131 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 255
Study 2122131 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 255
Study 7427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg four times daily for seven days
Number of subjects: 200
Study 7427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 500 mg four times daily for seven days
Number of subjects: 200
Study 7427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (250 mg and 500 mg)
Number of subjects: 200
Study 31647886 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental whey protein (PRO) 25 g, 3×/day for 12 weeks
Number of subjects: 21
Study 31647886 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PLA) 25 g, 3×/day for 12 weeks
Number of subjects: 21
Study 30069754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health conditions (e.g., schizophrenia, obsessive compulsive disorder)
Number of subjects: 13000
Study 30069754 — intervention group
Group type: COMPARATOR
Intervention: Physical health conditions
Number of subjects: 13000
Study 26963724 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy (LA group)
Number of subjects: 180
Study 25815419 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008
Study 25815419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study 25815419 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine
Number of subjects: 1008
Study 25815419 — intervention group
Group type: EXPERIMENTAL
Intervention: All subtype groups
Number of subjects: 1008
Study 22916715 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 197
Study 22916715 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine
Number of subjects: 197
Study 20022408 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 0
Study 20022408 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 19258384 — intervention group
Group type: EXPERIMENTAL
Intervention: LF (Balance, Fresenius)
Number of subjects: 91
Study 19258384 — intervention group
Group type: COMPARATOR
Intervention: CF (CAPD/DPCA, Fresenius)
Number of subjects: 91
Study 17609405 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin levels >5 pmol/l with blood glucose levels <2.5 mmol/l during a 72 h fast test
Number of subjects: 100
Study 17609405 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide levels >0.2 nmol/l
Number of subjects: 100
Study 17609405 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinsulin levels >22 pmol/l
Number of subjects: 100
Study 17609405 — intervention group
Group type: COMPARATOR
Intervention: Proinsulin levels <22 pmol/l
Number of subjects: 100
Study 15308521 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly oral azithromycin for 13 weeks (1 g single dose for Chlamydia infection)
Number of subjects: 186
Study 15308521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 11355895 — intervention group
Group type: EXPERIMENTAL
Intervention: rEpo administration (30 IU/kg)
Number of subjects: 18
Study 11355895 — intervention group
Group type: EXPERIMENTAL
Intervention: rEpo administration (various treatments)
Number of subjects: 18
Study 11355895 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric formula including hematocrit value, reticulocyte count, soluble transferrin receptor content, and beta-globin mRNA concentration
Number of subjects: 18
Study 9743816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 1200 mg/day
Number of subjects: 127
Study 9743816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 3 x 400 mg/day
Number of subjects: 127
Study 9743816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 9743816 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall efficacy assessments (physician's and patient's)
Number of subjects: 127
Study 7999489 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 96
Study 7999489 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 0.15 mg kg‐1
Number of subjects: 96
Study 3382159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g I.V. as a single injection performed 1 hour before ESWL
Number of subjects: 50
Study 3382159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30789580 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Stockings (20-30 mm Hg)
Number of subjects: 20
Study 30789580 — intervention group
Group type: COMPARATOR
Intervention: Control (non-CS)
Number of subjects: 20
Study 29911435 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary committee recommendations for MAOEs
Number of subjects: 145
Study 29911435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) therapy recommendations
Number of subjects: 145
Study 29911435 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication administration record (MAR) recommendations
Number of subjects: 145
Study 28913543 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0
Study 28913543 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 0
Study 28436359 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy (BT)
Number of subjects: 165
Study 28436359 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 165
Study 26356808 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER delivery system
Number of subjects: 28
Study 26356808 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 28
Study 24046412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis spores
Number of subjects: 10
Study 24046412 — intervention group
Group type: EXPERIMENTAL
Intervention: polyinosinic‐polycytidylic acid
Number of subjects: 10
Study 24046412 — intervention group
Group type: EXPERIMENTAL
Intervention: CpG oligodeoxynucleotides (CpG-ODN)
Number of subjects: 10
Study 22081189 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1mg)
Number of subjects: 60
Study 22081189 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4mg)
Number of subjects: 60
Study 18652326 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Jingming (BL 1), Taiyang (EX‐HN 5), Chengqi (ST 1), Hegu (LI4)
Number of subjects: 80
Study 18652326 — intervention group
Group type: COMPARATOR
Intervention: Eye drug treatment with local dropping of Aiweiduo
Number of subjects: 80
Study 18652326 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 80
Study 18652326 — intervention group
Group type: COMPARATOR
Intervention: Eye drug treatment
Number of subjects: 80
Study 16409197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at maintenance doses of 20, 2,000, and 20,000 SQ‐U weekly for 1 year.
Number of subjects: 89
Study 16409197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy (SIT) with house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) at higher doses (2,000 and 20,000 SQ‐U).
Number of subjects: 89
Study 15199077 — intervention group
Group type: EXPERIMENTAL
Intervention: DRF-1042 at 120 mg/m(2)/day
Number of subjects: 25
Study 15199077 — intervention group
Group type: EXPERIMENTAL
Intervention: DRF-1042 at 1.5 to 270 mg/m(2)
Number of subjects: 25
Study 15199077 — intervention group
Group type: EXPERIMENTAL
Intervention: DRF-1042
Number of subjects: 25
Study 11336165 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 concentration in colorectal cancer patients
Number of subjects: 94
Study 11336165 — intervention group
Group type: COMPARATOR
Intervention: Tissue sICAM‐1 concentration in normal mucosa
Number of subjects: 94
Study 11336165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue sICAM‐1 concentration in advanced carcinoma
Number of subjects: 94
Study 11336165 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAM‐1 immunoreactivity in tumor
Number of subjects: 94
Study 11336165 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sICAM‐1 level
Number of subjects: 94
Study 9391857 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler color flow imaging technique
Number of subjects: 30
Study 9391857 — intervention group
Group type: COMPARATOR
Intervention: Conventional left ventricular outflow method
Number of subjects: 30
Study 7930386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 50 mg orally 2 hours before blood collection
Number of subjects: 13
Study 7930386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 13
Study 3286384 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 10 mg bolus injection iv followed by continuous infusions of 3.2 mg/h
Number of subjects: 12
Study 3286384 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 10 mg bolus injection iv followed by continuous infusions of 4 mg/h
Number of subjects: 12
Study 3286384 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 28485994 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation and suction (IS)
Number of subjects: 260
Study 28485994 — intervention group
Group type: COMPARATOR
Intervention: Suction only (SO)
Number of subjects: 260
Study 26970723 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks
Number of subjects: 287
Study 26970723 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 287
Study 26970723 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 287
Study 26970723 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 287
Study 24372888 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome‐paced speech condition
Number of subjects: 13
Study 24372888 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 13
Study 23598083 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related training (TRT)
Number of subjects: 21
Study 23598083 — intervention group
Group type: COMPARATOR
Intervention: Standardized outcome measures
Number of subjects: 21
Study 20949847 — intervention group
Group type: EXPERIMENTAL
Intervention: WCG3 (waist circumference >= 90 cm)
Number of subjects: 84
Study 20949847 — intervention group
Group type: COMPARATOR
Intervention: WCG1 (waist circumference < 70 cm)
Number of subjects: 84
Study 20949847 — intervention group
Group type: COMPARATOR
Intervention: WCG2 (waist circumference between 70 and 89 cm)
Number of subjects: 84
Study 20949847 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and SFAB
Number of subjects: 84
Study 20949847 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 84
Study 19140646 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training (twice weekly for 3 months)
Number of subjects: 80
Study 19140646 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 80
Study 16766587 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC with primary prophylactic G-CSF (PPG)
Number of subjects: 1047
Study 16766587 — intervention group
Group type: COMPARATOR
Intervention: TAC without PPG
Number of subjects: 1047
Study 16766587 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 1047
Study 16766587 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC with PPG
Number of subjects: 1047
Study 12559639 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome (death plus disease occurrence or recurrence)
Number of subjects: 0
Study 12559639 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality outcome
Number of subjects: 0
Study 12559639 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome
Number of subjects: 0
Study 12559639 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (Bonferroni method)
Number of subjects: 0
Study 12559639 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (joint distribution of test statistics)
Number of subjects: 0
Study 12559639 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 10404768 — intervention group
Group type: EXPERIMENTAL
Intervention: FV:R506Q mutation (prevalence 2.5%)
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives or hormone replacement therapy
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Smoking markers
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Gender (Women vs Men)
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol and diastolic blood pressure
Number of subjects: 955
Study 10404768 — intervention group
Group type: COMPARATOR
Intervention: Triglycerides, systolic blood pressure, and body mass index (in women)
Number of subjects: 955
Study 7861317 — intervention group
Group type: EXPERIMENTAL
Intervention: Latinos distinguishing between their own subgroup and others
Number of subjects: 3
Study 7861317 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of the term Hispanic
Number of subjects: 3
Study 7861317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup differentiation based on positive distinctiveness
Number of subjects: 3
Study 2672868 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine (30 mg)
Number of subjects: 20
Study 2672868 — intervention group
Group type: COMPARATOR
Intervention: Epidural diamorphine (5 mg)
Number of subjects: 20
Study 333601 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral cefazolin begun before operation
Number of subjects: 0
Study 333601 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic present in the tissues at the time of inoculation or resistant bacteria
Number of subjects: 0
Study 30293666 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1606
Study 30293666 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1606
Study 28720980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation Therapy (CRT)
Number of subjects: 30
Study 28720980 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE)
Number of subjects: 30
Study 28720980 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study 26200164 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft with equine origin (Apatos, Osteobiol; Tecnoss Dental)
Number of subjects: 8
Study 26200164 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft (1 g) + porous titanium (1 g) granules (Natix; Tigran Technologies AB)
Number of subjects: 8
Study 24599947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful attention manipulation
Number of subjects: 198
Study 24599947 — intervention group
Group type: EXPERIMENTAL
Intervention: State mindfulness
Number of subjects: 198
Study 24599947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 21987227 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular cognitive behavioral therapy (CBT)
Number of subjects: 24